Capmatinib
- TRADE NAME: Tabrecta (Novartis)
- INDICATIONS:
Metastatic non-small cell lung cancer in adult patients.
NOTE: (2020) FDA approved under accelerated approval based on overall response rate and duration of response. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- SYNONYM: Capmatinib hydrochloride
- CLASS: Kinase inhibitor, MET (mesenchymal-epithelial transition) inhibitor
- HALF-LIFE: 6.5 hours
FDA APPROVAL DATE: 05/06/2020
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:CYP3A inducers, CYP3A inhibitors, Itraconazole, Rabeprazole, Rifampin
Can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 02/10/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations 
- Breast feeding
- Geriatric
- Pediatric